Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China.
Frontiers in immunology（2023）
关键词
toripalimab,PD-1,cost-effectiveness,partitioned survival model,advanced non-small cell lung cancer (advanced NSCLC),chemothearpy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要